Clinically, FABP7 has been implicated in a wide range of diseases including cancer, Down’s syndrome, schizophrenia, and the neurodegenerative diseases amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and Alzheimer’s disease (AD; Sánchez-Font et al., 2003; Watanabe et al., 2007; Teunissen et al., 2011; De Rosa et al., 2012; Thumser et al., 2014; Islam et al., 2019). This evidence concerns the gene FABP7 and early-onset autosomal dominant Alzheimer disease.